• Explore /
  • Poster
  • / Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

Abstract Video & Slides Poster

Authors

Amit Oza

Amit M. Oza

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Amit M. Oza , Alla Sergeevna Lisyanskaya , Alexander A. Fedenko , Mikhail Dvorkin , Andreia Cristina de Melo , Yaroslav V. Shparyk , Irina Rakhmatullina , Igor Bondarenko , Nicoletta Colombo , Valentyn Svintsitskiy , David Cibula , Róbert Póka , Ana Oaknin , Tamar Safra , Beata Mackowiak-Matejczyk , Ling Ma , Karen Retta McLachlan , Sandra Goble , Rebecca Sophie Kristeleit

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02855944

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5517)

DOI

10.1200/JCO.2021.39.15_suppl.5517

Abstract #

5517

Abstract Disclosures

Similar Posters

First Author: Amit M. Oza

First Author: Thomas Powles

First Author: Charlie Gourley

First Author: Helena Alexandra Yu